Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 20Unknown 5Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Myelodysplastic Syndromes 13Anemia, Refractory, with Excess of Blasts 11Myeloproliferative Disorders 9Leukemia, Myeloid, Acute 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Hematologic Neoplasms 8Lymphoma, Non-Hodgkin 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Anemia, Aplastic 7Anemia 7Lymphoma 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Lymphocytic, Chronic, B-Cell 6Multiple Myeloma 5Leukemia 5Hodgkin Disease 5Venous Thromboembolism 4Primary Myelofibrosis 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 3Primary Immunodeficiency Diseases 3Neoplasms, Plasma Cell 3Neoplasms 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Bone Marrow Failure Disorders 3Thrombocythemia, Essential 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fanconi Anemia, Complementation Group D1 × Classical hematology × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡